Slone Partners Recruits Chief Business Officer for Arpeggio Biosciences

June 7, 2024 – Life sciences-focused search firm Slone Partners has recruited Kevin Eastwood as chief business officer of Arpeggio Biosciences in South Riding, VA. “Kevin Eastwood is a highly accomplished and dynamic business leader with extraordinary passion and vision and a track record of success,” said Leslie Loveless, managing partner and CEO at Slone Partners. “He brings a high level of strategic management and business development to the outstanding leadership team at Arpeggio.”

“We are thrilled to join forces with Kevin,” said Joey Azofeifa, CEO at Arpeggio. “With over 20 years of experience in business development, at Gilead and platform technology companies like Plexium and Ambrx, Kevin is the ideal person to elevate our functional genomics approach to targeting transcription factors to new heights.”

Mr. Eastwood has more than 25 years of experience in senior leadership roles at innovative pharmaceutical and therapeutics companies across the nation. Most recently he served as executive vice president, corporate development at Plexium, Inc., where he helped secure a $35 million series A-2 financing and $102M series B financing and established two multi-target, multi-year drug discovery collaborations, one with Amgen in the oncology disease area and a second with AbbVie in neuroscience. In prior roles, Mr. Eastwood served as vice president, corporate development at the California Institute for Biomedical Research and the Scripps Research Institute; senior director, corporate development, Gilead Sciences, Inc.; and startup founder and senior vice president, corporate development, Effector Therapeutics, Inc.

“I am grateful for the opportunity to join Arpeggio Biosciences to support its mission to transform the discovery of therapeutics that correct dysregulated transcription,” said Mr. Eastwood. “Arpeggio’s HTS transcriptomics platform GRETA provides a novel approach for identifying small molecule transcription modulators, providing an opportunity to drug transcription factors, historically viewed as undruggable targets.”

Related: Slone Partners Recruits Co-CEO for EarlyDiagnostics

Arpeggio Biosciences is a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease. It is drugging transcription factors using AI and rapid RNA-sequencing. Powered by laboratory automation, Arpeggio discovers drugs based on not just a single target, but the entire cellular network. Arpeggio is currently progressing drug programs towards clinical studies in oncology and chronic kidney disease.

Serving the Healthcare & Life Sciences Sectors

Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”

Slone Partners Recruits Chief Medical Officer for Carisma Therapeutics

Slone Partners recently placed Eugene P. Kennedy as chief medical officer at Carisma Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.

“Dr. Kennedy is a highly accomplished and respected physician, healthcare executive, and thought leader with extraordinary vision and passion and a history of driving successful new ventures across various therapeutic areas,” said Jennifer Lemasters, senior vice president, executive search, and partner at Slone Partners. “He comes to Carisma at an exciting time in its evolution and will be a tremendous addition to its leadership team.”

In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.

Ms. Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.

Related: Slone Partners Recruits CEO for Magnetic Insight

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Executive Editor; Lily Fauver, Senior Editor – Hunt Scanlon Media

Share This Article


Notify of
Inline Feedbacks
View all comments